Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. (Q47594270)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. (English)

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

1 reference

based on heuristic

inferred from title

David Flockhart

10

object named as

David A Flockhart

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

9

object named as

Vered Stearns

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Anna Maria V. Storniolo

8

object named as

Anna M Storniolo

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

3

object named as

Anne T Nguyen

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

11

object named as

Todd C Skaar

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

1

object named as

Jason D Robarge

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Zereunesay Desta

2

object named as

Zereunesay Desta

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

6

object named as

James M Rae

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

author name string

Lang Li

4

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Daniel Hertz

5

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Daniel F Hayes

7

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

N Lynn Henry

12

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

language of work or name

0 references

publication date

9 December 2016

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

161

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

3

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

453-461

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

https://scigraph.springernature.com/pub.10.1007/s10549-016-4077-4

0 references

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Interpreting plasma estrogen levels in breast cancer: caution needed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Predictors of recovery of ovarian function during aromatase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Challenges to the measurement of estradiol: an endocrine society position statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

22 May 2018

Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Measurement of estradiol--challenges ahead

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Standardization of steroid hormone assays: why, how, and when?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Comparison of methods to measure low serum estradiol levels in postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

14 August 2018

Constitutive Expression of the Steroid Sulfatase Gene Supports the Growth of MCF-7 Human Breast Cancer Cellsin Vitroandin Vivo1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5429096

29 September 2018

Associations among Mammographic Density, Circulating Sex Hormones, and Polymorphisms in Sex Hormone Metabolism Genes in Postmenopausal Women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-4077-4

21 January 2018

Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/27943008

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27943008

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estrone sulfate: a potential source of estradiol in human breast cancer tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/27943008

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/27943008

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27943008

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10549-016-4077-4

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

1 reference

Europe PubMed Central

4 February 2018

http://europepmc.org/abstract/PMC/5429096

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47594270&oldid=1962329565"